Sphingolipid signalling in the cardiovascular system: Good, bad or both?

European Journal of Pharmacology

Volumn 585, Issue 2-3, 2008, Pages 292-302

  Alewijnse, Astrid E ^a   Peters, Stephan L M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Atherogenesis; Blood pressure; Cardioprotection; HDL; Insulin resistance; Lipoprotein; Sphingosine 1 phosphate receptor

Indexed keywords

5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; CERAMIDE; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL TYPE; CLINICAL FEATURE; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DRUG RESEARCH; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HEART DISEASE; HEART FUNCTION; HEART RATE; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR PHYSIOLOGY; DIABETES MELLITUS; HEART DISEASES; HUMANS; HYPERTENSION; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

EID: 43049085142     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.02.089     Document Type: Review

References (153)

1. Adams II J.M., Pratipanawatr T., Berria R., Wang E., DeFronzo R.A., Sullards M.C., and Mandarino L.J. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53 (2004) 25-31
2. Adamy C., Mulder P., Khouzami L., Andrieu-Abadie N., Defer N., Candiani G., Pavoine C., Caramelle P., Souktani R., Le Corvoisier P., Perier M., Kirsch M., Damy T., Berdeaux A., Levade T., Thuillez C., Hittinger L., and Pecker F. Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. J. Mol. Cell. Cardiol. 43 (2007) 344-353
3. Alemany R., van Koppen C.J., Danneberg K., Ter Braak M., and Meyer zu Heringdorf D. Regulation and functional roles of sphingosine kinases. Naunyn Schmiedeberg's Arch. Pharmacol. 374 (2007) 413-428
4. Alewijnse A.E., Peters S.L., and Michel M.C. Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br. J. Pharmacol. 143 (2004) 666-684
5. Anderson T.J. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail. Rev. 8 (2003) 71-86
6. Aoki S., Yatomi Y., Shimosawa T., Yamashita H., Kitayama J., Tsuno N.H., Takahashi K., and Ozaki Y. The suppressive effect of sphingosine 1-phosphate on monocyte-endothelium adhesion may be mediated by the rearrangement of the endothelial integrins alpha(5)beta(1) and alpha(v)beta(3). J. Thromb. Haemost. 5 (2007) 1292-1301
7. Argraves K.M., and Argraves W.S. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J. Lipid Res. 48 (2007) 2325-2333
8. Assmann G., and Nofer J.R. Atheroprotective effects of high-density lipoproteins. Annu. Rev. Med. 54 (2003) 321-341
9. Auge N., Negre-Salvayre A., Salvayre R., and Levade T. Sphingomyelin metabolites in vascular cell signaling and atherogenesis. Prog. Lipid Res. 39 (2000) 207-229
10. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ. Res. 95 (2004) 764-772
11. Barter P.J., Puranik R., and Rye K.A. New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr. Cardiol. Rep. 9 (2007) 493-498
12. Bischoff A., Czyborra P., Meyer Zu Heringdorf D., Jakobs K.H., and Michel M.C. Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner. Br. J. Pharmacol. 130 (2000) 1878-1883
13. Bischoff A., Meyer Zu Heringdorf D., Jakobs K.H., and Michel M.C. Lysosphingolipid receptor-mediated diuresis and natriuresis in anaesthetized rats. Br. J. Pharmacol. 132 (2001) 1925-1933
14. Bolick D.T., Srinivasan S., Kim K.W., Hatley M.E., Clemens J.J., Whetzel A., Ferger N., Macdonald T.L., Davis M.D., Tsao P.S., Lynch K.R., and Hedrick C.C. Sphingosine-1-phosphate prevents tumor necrosis factor-alpha-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 976-981
15. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 115 (2007) 84-105
16. Brown B.A., Kantesaria P.P., and McDevitt L.M. Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann. Pharmacother. 41 (2007) 1660-1668
17. Cailleret M., Amadou A., Andrieu-Abadie N., Nawrocki A., Adamy C., Ait-Mamar B., Rocaries F., Best-Belpomme M., Levade T., Pavoine C., and Pecker F. N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes. Circulation 109 (2004) 406-411
18. Chalfant C.E., and Spiegel S. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J. Cell. Sci. 118 (2005) 4605-4612
19. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1523-1533
20. Chavez J.A., Knotts T.A., Wang L.P., Li G., Dobrowsky R.T., Florant G.L., and Summers S.A. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J. Biol. Chem. 278 (2003) 10297-10303
21. Chen X.L., Grey J.Y., Thomas S., Qiu F.H., Medford R.M., Wasserman M.A., and Kunsch C. Sphingosine kinase-1 mediates TNF-alpha-induced MCP-1 gene expression in endothelial cells: upregulation by oscillatory flow. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H1452-H1458
22. Chun J., Goetzl E.J., Hla T., Igarashi Y., Lynch K.R., Moolenaar W., Pyne S., and Tigyi G. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 54 (2002) 265-269
23. Coroneos E., Martinez M., McKenna S., and Kester M. Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. Implications for cellular proliferation and differentiation. J. Biol. Chem. 270 (1995) 23305-23309
24. Coussin F., Scott R.H., Wise A., and Nixon G.F. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ. Res. 91 (2002) 151-157
25. Davignon J., and Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109 (2004) III27-III32
26. Deutschman D.H., Carstens J.S., Klepper R.L., Smith W.S., Page M.T., Young T.R., Gleason L.A., Nakajima N., and Sabbadini R.A. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am. Heart J. 146 (2003) 62-68
27. Dev K.K., Mullershausen F., Mattes H., Kuhn R.R., Bilbe G., Hoyer D., and Mir A. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol. Ther. 117 (2008) 77-93
28. Doehner W., Bunck A.C., Rauchhaus M., von Haehling S., Brunkhorst F.M., Cicoira M., Tschope C., Ponikowski P., Claus R.A., and Anker S.D. Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur. Heart J. 28 (2007) 821-828
29. Duan H.F., Wang H., Yi J., Liu H.J., Zhang Q.W., Li L.B., Zhang T., Lu Y., Wu C.T., and Wang L.S. Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Hum. Gene Ther. 18 (2007) 1119-1128
30. Edmunds N.J., Lal H., and Woodward B. Effects of tumour necrosis factor-alpha on left ventricular function in the rat isolated perfused heart: possible mechanisms for a decline in cardiac function. Br. J. Pharmacol. 126 (1999) 189-196
31. Forrest M., Sun S.Y., Hajdu R., Bergstrom J., Card D., Doherty G., Hale J., Keohane C., Meyers C., Milligan J., Mills S., Nomura N., Rosen H., Rosenbach M., Shei G.J., Singer I.I., Tian M., West S., White V., Xie J., Proia R.L., and Mandala S. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J. Pharmacol. Exp. Ther. 309 (2004) 758-768
32. Fu F., Hu S., Deleo J., Li S., Hopf C., Hoover J., Wang S., Brinkmann V., Lake P., and Shi V.C. Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation 73 (2002) 1425-1430
33. Futerman A.H., and Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol. 15 (2005) 312-318
34. Geoffroy K., Wiernsperger N., Lagarde M., and El Bawab S. Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids. J. Biol. Chem. 279 (2004) 34343-34352
35. Graham D., McBride M.W., Gaasenbeek M., Gilday K., Beattie E., Miller W.H., McClure J.D., Polke J.M., Montezano A., Touyz R.M., and Dominiczak A.F. Candidate genes that determine response to salt in the stroke-prone spontaneously hypertensive rat: congenic analysis. Hypertension 50 (2007) 1134-1141
36. Grant M.B., Afzal A., Spoerri P., Pan H., Shaw L.C., and Mames R.N. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin. Investig. Drugs 13 (2004) 1275-1293
37. Hannun Y.A. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 269 (1994) 3125-3128
38. Hannun Y.A., and Bell R.M. The sphingomyelin cycle: a prototypic sphingolipid signaling pathway. Adv. Lipid Res. 25 (1993) 27-41
39. Hannun Y.A., and Obeid L.M. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J. Biol. Chem. 277 (2002) 25847-25850
40. Hannun Y.A., Loomis C.R., Merrill Jr. A.H., and Bell R.M. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J. Biol. Chem. 261 (1986) 12604-12609
41. Hansson G.K., and Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6 (2006) 508-519
42. Hemmings D.G. Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine. Naunyn Schmiedeberg's Arch. Pharmacol. 373 (2006) 18-29
43. Hoff H.F., and Morton R.E. Lipoproteins containing apo B extracted from human aortas. Structure and function. Ann. N. Y. Acad. Sci. 454 (1985) 183-194
44. Igarashi J., Bernier S.G., and Michel T. Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. Differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J. Biol. Chem. 276 (2001) 12420-12426
45. Igarashi J., Thatte H.S., Prabhakar P., Golan D.E., and Michel T. Calcium-independent activation of endothelial nitric oxide synthase by ceramide. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 12583-12588
46. Ishii I., Friedman B., Ye X., Kawamura S., McGiffert C., Contos J.J., Kingsbury M.A., Zhang G., Brown J.H., and Chun J. Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J. Biol. Chem. 276 (2001) 33697-33704
47. Jin Z.Q., Zhang J., Huang Y., Hoover H.E., Vessey D.A., and Karliner J.S. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc. Res. 76 (2007) 41-50
48. Jin Z.Q., Zhou H.Z., Zhu P., Honbo N., Mochly-Rosen D., Messing R.O., Goetzl E.J., Karliner J.S., and Gray M.O. Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 282 (2002) H1970-H1977
49. Jongsma M., Hendriks-Balk M.C., Michel M.C., Peters S.L., and Alewijnse A.E. BML-241 fails to display selective antagonism at the sphingosine-1-phosphate receptor, S1P(3). Br. J. Pharmacol. 149 (2006) 277-282
50. Kang J.S., Yoon Y.D., Han M.H., Han S.B., Lee K., Lee K.H., Park S.K., and Kim H.M. Glabridin suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking sphingosine kinase pathway: implications of Akt, extracellular signal-regulated kinase, and nuclear factor-kappaB/Rel signaling pathways. Mol. Pharmacol. 69 (2006) 941-949
51. Karliner J.S., Honbo N., Summers K., Gray M.O., and Goetzl E.J. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J. Mol. Cell. Cardiol. 33 (2001) 1713-1717
52. Kase H., Hattori Y., Jojima T., Okayasu T., Tomizawa A., Suzuki K., Banba N., Monden T., Satoh H., Akimoto K., and Kasai K. Globular adiponectin induces adhesion molecule expression through the sphingosine kinase pathway in vascular endothelial cells. Life Sci. 81 (2007) 939-943
53. Keul P., Tolle M., Lucke S., von Wnuck Lipinski K., Heusch G., Schuchardt M., van der Giet M., and Levkau B. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 607-613
54. Kihara A., Mitsutake S., Mizutani Y., and Igarashi Y. Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate. Prog. Lipid Res. 46 (2007) 126-144
55. Kimura T., Sato K., Kuwabara A., Tomura H., Ishiwara M., Kobayashi I., Ui M., and Okajima F. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 276 (2001) 31780-31785
56. Kimura T., Sato K., Malchinkhuu E., Tomura H., Tamama K., Kuwabara A., Murakami M., and Okajima F. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1283-1288
57. Kimura T., Tomura H., Mogi C., Kuwabara A., Ishiwara M., Shibasawa K., Sato K., Ohwada S., Im D.S., Kurose H., Ishizuka T., Murakami M., and Okajima F. Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells. Cell Signal 18 (2006) 841-850
58. Klawitter S., Hofmann L.P., Pfeilschifter J., and Huwiler A. Extracellular nucleotides induce migration of renal mesangial cells by upregulating sphingosine kinase-1 expression and activity. Br. J. Pharmacol. 150 (2007) 271-280
59. Klingenberg R., Nofer J.R., Rudling M., Bea F., Blessing E., Preusch M., Grone H.J., Katus H.A., Hansson G.K., and Dengler T.J. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2392-2399
60. Kluk M.J., and Hla T. Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ. Res. 89 (2001) 496-502
61. Lahiri S., and Futerman A.H. The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci. 64 (2007) 2270-2284
62. LaMontagne K., Littlewood-Evans A., Schnell C., O'Reilly T., Wyder L., Sanchez T., Probst B., Butler J., Wood A., Liau G., Billy E., Theuer A., Hla T., and Wood J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 66 (2006) 221-231
63. Laychock S.G., Sessanna S.M., Lin M.H., and Mastrandrea L.D. Sphingosine 1-phosphate affects cytokine-induced apoptosis in rat pancreatic islet beta-cells. Endocrinology 147 (2006) 4705-4712
64. Laychock S.G., Tian Y., and Sessanna S.M. Endothelial differentiation gene receptors in pancreatic islets and INS-1 cells. Diabetes 52 (2003) 1986-1993
65. Le Stunff H., Milstien S., and Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J. Cell. Biochem. 92 (2004) 882-899
66. Lecour S., Smith R.M., Woodward B., Opie L.H., Rochette L., and Sack M.N. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J. Mol. Cell. Cardiol. 34 (2002) 509-518
67. Lee M.J., Thangada S., Liu C.H., Thompson B.D., and Hla T. Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist. J. Biol. Chem. 273 (1998) 22105-22112
68. Levkau B., Hermann S., Theilmeier G., van der Giet M., Chun J., Schober O., and Schäfers M. High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation 110 (2004) 3355-3359
69. Li H., Junk P., Huwiler A., Burkhardt C., Wallerath T., Pfeilschifter J., and Förstermann U. Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation 106 (2002) 2250-2256
70. Li X.A., Titlow W.B., Jackson B.A., Giltiay N., Nikolova-Karakashian M., Uittenbogaard A., and Smart E.J. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J. Biol. Chem. 277 (2002) 11058-11063
71. Liu B., Andrieu-Abadie N., Levade T., Zhang P., Obeid L.M., and Hannun Y.A. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J. Biol. Chem. 273 (1998) 11313-11320
72. Lorenz J.N., Arend L.J., Robitz R., Paul R.J., and MacLennan A.J. Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292 (2007) R440-R446
73. Ma M.M., Chen J.L., Wang G.G., Wang H., Lu Y., Li J.F., Yi J., Yuan Y.J., Zhang Q.W., Mi J., Wang L.S.h., Duan H.F., and Wu C.T. Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice. Diabetologia 50 (2007) 891-900
74. Maceyka M., Payne S.G., Milstien S., and Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim. Biophys. Acta. 1585 (2002) 193-201
75. Maceyka M., Sankala H., Hait N.C., Le Stunff H., Liu H., Toman R., Collier C., Zhang M., Satin L.S., Merrill Jr. A.H., Milstien S., and Spiegel S. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem. 280 (2005) 37118-37129
76. Maines L.W., French K.J., Wolpert E.B., Antonetti D.A., and Smith C.D. Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases. Invest Ophthalmol. Vis. Sci. 47 (2006) 5022-5031
77. Major C.D., Gao Z.Y., and Wolf B.A. Activation of the sphingomyelinase/ceramide signal transduction pathway in insulin-secreting beta-cells: role in cytokine-induced beta-cell death. Diabetes 48 (1999) 1372-1380
78. Mandrup-Poulsen T. Beta-cell apoptosis: stimuli and signaling. Diabetes 50 Suppl 1 (2001) S58-S63
79. Mastrandrea L.D., Sessanna S.M., and Laychock S.G. Sphingosine kinase activity and sphingosine-1 phosphate production in rat pancreatic islets and INS-1 cells: response to cytokines. Diabetes 54 (2005) 1429-1436
80. Means C.K., Xiao C.Y., Li Z., Zhang T., Omens J.H., Ishii I., Chun J., and Brown J.H. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H2944-H2951
81. Menaldino D.S., Bushnev A., Sun A., Liotta D.C., Symolon H., Desai K., Dillehay D.L., Peng Q., Wang E., Allegood J., Trotman-Pruett S., Sullards M.C., and Merrill Jr. A.H. Sphingoid bases and de novo ceramide synthesis: enzymes involved, pharmacology and mechanisms of action. Pharmacol. Res. 47 (2003) 373-381
82. Meyer zu Heringdorf D., and Jakobs K.H. Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim. Biophys. Acta 1768 (2007) 923-940
83. Michel M.C., Mulders A.C., Jongsma M., Alewijnse A.E., and Peters S.L. Vascular effects of sphingolipids. Acta Paediatr. (Oslo, Norway: 1992) 96 (2007) 44-48 Supplement
84. Mineo C., Deguchi H., Griffin J.H., and Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ. Res. 98 (2006) 1352-1364
85. Mulders A.C., Hendriks-Balk M.C., Mathy M.J., Michel M.C., Alewijnse A.E., and Peters S.L. Sphingosine kinase-dependent activation of endothelial nitric oxide synthase by angiotensin II. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2043-2048
86. Mulders A.C., Peters S.L., and Michel M.C. Sphingomyelin metabolism and endothelial cell function. Eur. Heart. J. 28 (2007) 777-779
87. Murata N., Sato K., Kon J., Tomura H., Yanagita M., Kuwabara A., Ui M., and Okajima F. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem. J. 352 Pt 3 (2000) 809-815
88. Naseem K.M. The role of nitric oxide in cardiovascular diseases. Mol. Aspects. Med. 26 (2005) 33-65
89. Nofer J.R., and Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc. Med. 15 (2005) 265-271
90. Nofer J.R., Bot M., Brodde M., Taylor P.J., Salm P., Brinkmann V., van Berkel T., Assmann G., and Biessen E.A. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 115 (2007) 501-508
91. Nofer J.R., Kehrel B., Fobker M., Levkau B., Assmann G., and von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161 (2002) 1-16
92. Nofer J.R., van der Giet M., Tölle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., Tietge U.J., Gödecke A., Ishii I., Kleuser B., Schäfers M., Fobker M., Zidek W., Assmann G., Chun J., and Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113 (2004) 569-581
93. Nofer J.R., Walter M., and Assmann G. Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence. Expert Rev. Cardiovasc. Ther. 3 (2005) 1071-1086
94. Ohanian J., and Ohanian V. Sphingolipids in mammalian cell signalling. Cell. Mol. Life Sci. 58 (2001) 2053-2068
95. Ohmori T., Yatomi Y., Osada M., Kazama F., Takafuta T., Ikeda H., and Ozaki Y. Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc. Res. 58 (2003) 170-177
96. Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator?. Biochim. Biophys. Acta 1582 (2002) 132-137
97. Oo M.L., Thangada S., Wu M.T., Liu C.H., Macdonald T.L., Lynch K.R., Lin C.Y., and Hla T. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 282 (2007) 9082-9089
98. Osawa Y., Banno Y., Nagaki M., Brenner D.A., Naiki T., Nozawa Y., Nakashima S., and Moriwaki H. TNF-alpha-induced sphingosine 1-phosphate inhibits apoptosis through a phosphatidylinositol 3-kinase/Akt pathway in human hepatocytes. J. Immunol. 167 (2001) 173-180
99. Payne S.G., Oskeritzian C.A., Griffiths R., Subramanian P., Barbour S.E., Chalfant C.E., Milstien S., and Spiegel S. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 109 (2007) 1077-1085
100. Peters S.L., and Alewijnse A.E. Sphingosine-1-phosphate signaling in the cardiovascular system. Curr. Opin. Pharmacol. 7 (2007) 186-192
101. Portman O.W., and Alexander M. Metabolism of sphingolipids by normal and atherosclerotic aorta of squirrel monkeys. J. Lipid Res. 11 (1970) 23-30
102. Pueyo M.E., Gonzalez W., Nicoletti A., Savoie F., Arnal J.F., and Michel J.B. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 645-651
103. Pyne S., and Pyne N.J. Sphingosine 1-phosphate signalling in mammalian cells. Biochem. J. 349 (2000) 385-402
104. Rasch R., and Norgaard J.O. Renal enlargement: comparative autoradiographic studies of 3H-thymidine uptake in diabetic and uninephrectomized rats. Diabetologia 25 (1983) 280-287
105. Roviezzo F., Bucci M., Delisle C., Brancaleone V., Di Lorenzo A., Mayo I.P., Fiorucci S., Fontana A., Gratton J.P., and Cirino G. Essential requirement for sphingosine kinase activity in eNOS-dependent NO release and vasorelaxation. FASEB J. 20 (2006) 340-342
106. Ruvolo P.P. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol. Res. 47 (2003) 383-392
107. Saba J.D., and Hla T. Point-counterpoint of sphingosine 1-phosphate metabolism. Circ. Res. 94 (2004) 724-734
108. Sachinidis A., Kettenhofen R., Seewald S., Gouni-Berthold I., Schmitz U., Seul C., Ko Y., and Vetter H. Evidence that lipoproteins are carriers of bioactive factors. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2412-2421
109. Salomone S., Potts E.M., Tyndall S., Ip P.C., Chun J., Brinkmann V., and Waeber C. Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. Br. J. Pharmacol. (2007)
110. Salomone S., Yoshimura S., Reuter U., Foley M., Thomas S.S., Moskowitz M.A., and Waeber C. S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur. J. Pharmacol. 469 (2003) 125-134
111. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
112. Schissel S.L., Schuchman E.H., Williams K.J., and Tabas I. Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. J. Biol. Chem. 271 (1996) 18431-18436
113. Schissel S.L., Tweedie-Hardman J., Rapp J.H., Graham G., Williams K.J., and Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J. Clin. Invest. 98 (1996) 1455-1464
114. Schmid G., Guba M., Ischenko I., Papyan A., Joka M., Schrepfer S., Bruns C.J., Jauch K.W., Heeschen C., and Graeb C. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J. Cell. Biochem. 101 (2007) 259-270
115. Schmid G., Guba M., Papyan A., Ischenko I., Bruckel M., Bruns C.J., Jauch K.W., and Graeb C. FTY720 inhibits tumor growth and angiogenesis. Transplant. Proc. 37 (2005) 110-111
116. Schmouder R., Serra D., Wang Y., Kovarik J.M., DiMarco J., Hunt T.L., and Bastien M.C. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J. Clin. Pharmacol. 46 (2006) 895-904
117. Shaul P.W. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J. Physiol. 547 (2003) 21-33
118. Shimamura K., Takashiro Y., Akiyama N., Hirabayashi T., and Murayama T. Expression of adhesion molecules by sphingosine 1-phosphate and histamine in endothelial cells. Eur. J. Pharmacol. 486 (2004) 141-150
119. Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim. Biophys. Acta 1582 (2002) 204-215
120. Singh I., Pahan K., Khan M., and Singh A.K. Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases. J. Biol. Chem. 273 (1998) 20354-20362
121. Skyschally A., Gres P., Hoffmann S., Haude M., Erbel R., Schulz R., and Heusch G. Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ. Res. 100 (2007) 140-146
122. Smith W.L., and Merrill Jr. A.H. Sphingolipid metabolism and signaling minireview series. J. Biol. Chem. 277 (2002) 25841-25842
123. Summers S.A. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 45 (2006) 42-72
124. Takuwa Y., Takuwa N., and Sugimoto N. The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. J. Biochem. 131 (2002) 767-771
125. Tamama K., Tomura H., Sato K., Malchinkhuu E., Damirin A., Kimura T., Kuwabara A., Murakami M., and Okajima F. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis 178 (2005) 19-23
126. Tani M., Ito M., and Igarashi Y. Ceramide/sphingosine/sphingosine 1-phosphate metabolism on the cell surface and in the extracellular space. Cell Signal 19 (2007) 229-237
127. Tani M., Kawakami A., Nagai M., Shimokado K., Kondo K., and Yoshida M. Sphingosine 1-phosphate (S1P) inhibits monocyte-endothelial cell interaction by regulating of RhoA activity. FEBS Lett. 581 (2007) 4621-4626
128. Theilmeier G., Schmidt C., Herrmann J., Keul P., Schäfers M., Herrgott I., Mersmann J., Larmann J., Hermann S., Stypmann J., Schober O., Hildebrand R., Schulz R., Heusch G., Haude M., von Wnuck Lipinski K., Herzog C., Schmitz M., Erbel R., Chun J., and Levkau B. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 114 (2006) 1403-1409
129. Thielmann M., Dorge H., Martin C., Belosjorow S., Schwanke U., van De Sand A., Konietzka I., Buchert A., Kruger A., Schulz R., and Heusch G. Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ. Res. 90 (2002) 807-813
130. Tiefenbacher C.P., and Kreuzer J. Nitric oxide-mediated endothelial dysfunction-is there need to treat?. Curr. Vasc. Pharmacol. 1 (2003) 123-133
131. Tölle M., Levkau B., Kleuser B., and van der Giet M. Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds. Eur J Clin Invest 37 (2007) 171-179
132. Truong W., Emamaullee J.A., Merani S., Anderson C.C., and James Shapiro A.M. Human islet function is not impaired by the sphingosine-1-phosphate receptor modulator FTY720. Am. J. Transplant. 7 (2007) 2031-2038
133. Tsukada Y.T., Sanna M.G., Rosen H., and Gottlieb R.A. S1P1-selective agonist SEW2871 exacerbates reperfusion arrhythmias. J. Cardiovasc. Pharmacol. 50 (2007) 660-669
134. Uittenbogaard A., Shaul P.W., Yuhanna I.S., Blair A., and Smart E.J. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J. Biol. Chem. 275 (2000) 11278-11283
135. Vann L.R., Payne S.G., Edsall L.C., Twitty S., Spiegel S., and Milstien S. Involvement of sphingosine kinase in TNF-alpha-stimulated tetrahydrobiopterin biosynthesis in C6 glioma cells. J. Biol. Chem. 277 (2002) 12649-12656
136. Veluthakal R., Jangati G.R., and Kowluru A. IL-1beta-induced iNOS expression, NO release and loss in metabolic cell viability are resistant to inhibitors of ceramide synthase and sphingomyelinase in INS 832/13 cells. J.O.P. 7 (2006) 593-601
137. Waeber C., Blondeau N., and Salomone S. Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors. Drug News Perspect. 17 (2004) 365-382
138. Whetzel A.M., Bolick D.T., Srinivasan S., Macdonald T.L., Morris M.A., Ley K., and Hedrick C.C. Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ. Res. 99 (2006) 731-739
139. Wu Y., Song P., Xu J., Zhang M., and Zou M.H. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J. Biol. Chem. 282 (2007) 9777-9788
140. Xia P. Letter by Xia regarding article, "High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor". Circulation 115 (2007) e393
141. Xia P., Gamble J.R., Rye K.A., Wang L., Hii C.S., Cockerill P., Khew-Goodall Y., Bert A.G., Barter P.J., and Vadas M.A. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14196-14201
142. Xia P., Vadas M.A., Rye K.A., Barter P.J., and Gamble J.R. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem. 274 (1999) 33143-33147
143. Xia P., Wang L., Gamble J.R., and Vadas M.A. Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. J. Biol. Chem. 274 (1999) 34499-34505
144. Xia P., Wang L., Moretti P.A., Albanese N., Chai F., Pitson S.M., D'Andrea R.J., Gamble J.R., and Vadas M.A. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. J. Biol. Chem. 277 (2002) 7996-8003
145. Xu C.B., Hansen-Schwartz J., and Edvinsson L. Sphingosine signaling and atherogenesis. Acta Pharmacol. Sin. 25 (2004) 849-854
146. Yang A.H., Ishii I., and Chun J. In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice. Biochim. Biophys. Acta 1582 (2002) 197-203
147. Yatomi Y. Plasma sphingosine 1-phosphate metabolism and analysis. Biochim. Biophys. Acta (2007) 10.1016/j.bbagen.2007.10.006
148. Yoshimura S., Banno Y., Nakashima S., Hayashi K., Yamakawa H., Sawada M., Sakai N., and Nozawa Y. Inhibition of neutral sphingomyelinase activation and ceramide formation by glutathione in hypoxic PC12 cell death. J. Neurochem. 73 (1999) 675-683
149. Young N., and Van Brocklyn J.R. Signal transduction of sphingosine-1-phosphate G protein-coupled receptors. Sci. World J. 6 (2006) 946-966
150. Yuhanna I.S., Zhu Y., Cox B.E., Hahner L.D., Osborne-Lawrence S., Lu P., Marcel Y.L., Anderson R.G., Mendelsohn M.E., Hobbs H.H., and Shaul P.W. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7 (2001) 853-857
151. Zhang D.X., Fryer R.M., Hsu A.K., Zou A.P., Gross G.J., Campbell W.B., and Li P.L. Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic. Res. Cardiol. 96 (2001) 267-274
152. Zhou X., and Hansson G.K. Immunomodulation and vaccination for atherosclerosis. Expert Opin. Biol. Ther. 4 (2004) 599-612
153. Zondag G.C., Postma F.R., Etten I.V., Verlaan I., and Moolenaar W.H. Sphingosine 1-phosphate signalling through the G-protein-coupled receptor Edg-1. Biochem. J. 330 (1998) 605-609